Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0LKHV)

• Drug Name: B7-2/GM-CSF Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Dementia	6D80-6D86	Phase 1	[1]
Dyslipidemia	5C80-5C81	Phase 1	[2]
Schizophrenia	6A20	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

• Cross-matching ID:
  PubChem CID: 9862248
  ChEBI ID: CHEBI:79988
  CAS Number: CAS 211110-63-3
  TTD Drug ID: DM0LKHV

Molecule-Related Drug Atlas

Drug(s) Targeting Muscarinic acetylcholine receptor M1 (CHRM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACECLIDINE	DMOLNCZ	Glaucoma/ocular hypertension	9C61	Approved	[6]
Fesoterodine fumarate	DM13495	Overactive bladder	GC50.0	Approved	[7]
SMT-D002	DM1I93C	Seborrhea	ED91.2	Approved	[8]
Clidinium	DMUMQZ0	Abdominal stomach pain	DD91.4	Approved	[9]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[10]
Oxyphenonium	DMMQHOZ	Visceral spasms	MD81.4	Approved	[11]
Benztropine	DMGZOVN	Parkinson disease	8A00.0	Approved	[12]
Glycopyrrolate	DM2M3ZA	Anaesthesia	9A78.6	Approved	[13]
Pirenzepine	DMP6M1N	Peptic ulcer	DA61	Approved	[14]
Cycrimine	DM8C43Q	Parkinson disease	8A00.0	Approved	[15]

Drug(s) Targeting Thyroid hormone receptor (THR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KB-5359	DMM7S3V	Lipid metabolism disorder	5C52.Z	Terminated	[16]
Neplanocin A	DMXULGK	Discovery agent	N.A.	Investigative	[17]
GC-14	DMYMGBA	Discovery agent	N.A.	Investigative	[17]
NH-3	DMYAB79	Discovery agent	N.A.	Investigative	[17]
NH-4	DMSUZFO	Discovery agent	N.A.	Investigative	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor M1 (CHRM1)	TTZ9SOR	ACM1_HUMAN	Agonist	[4]
Thyroid hormone receptor (THR)	TTQWUPT	NOUNIPROTAC	Agonist	[5]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028844)
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2639).
• [3] GM-CSF-Secreting Vaccines for Solid Tumors: Moving Forward. Discov Med. 2010 July; 10(50): 52-60.
• [4] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [5] Sobetirome: a case history of bench-to-clinic drug discovery and development. Heart Fail Rev. 2010 Mar;15(2):177-82.
• [6] Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [8] Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
• [9] Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460.
• [10] The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301.
• [11] Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62.
• [12] Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60.
• [13] Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
• [14] Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31.
• [15] Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [17] Design of thyroid hormone receptor antagonists from first principles. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):59-73.